DeLong Mark Jeffrey
Chief Business & Strat Officer
DeLong Mark Jeffrey has filed 6 SEC Form 4 filings (17 transaction rows) across 1 company, with disclosures dating back to 2026. 6 of those filings fall inside the rolling window. Most recent filing: May 14, 2026.
On the most recent filing, DeLong Mark Jeffrey is listed as Chief Business & Strat Officer at Apellis Pharmaceuticals, Inc. Inside the rolling window, DeLong Mark Jeffrey reported no open-market purchases and 4 open-market sales totaling $147K in APLS. The largest disclosed transaction in the window is a sale of 3,371 APLS shares on Jan 22, 2026, worth $73K.
Companies traded
Other insiders at APLS
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$147K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has DeLong Mark Jeffrey made?
DeLong Mark Jeffrey has filed 6 SEC Form 4 filings (17 transaction rows) across 1 company since 2026.
Which companies does DeLong Mark Jeffrey trade?
DeLong Mark Jeffrey has filed SEC Form 4 disclosures for 1 company, including APLS.
When was DeLong Mark Jeffrey's most recent SEC Form 4 filing?
DeLong Mark Jeffrey's most recent SEC Form 4 filing on Tracefour is dated May 14, 2026.
What is DeLong Mark Jeffrey's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, DeLong Mark Jeffrey is listed as Chief Business & Strat Officer.
What is DeLong Mark Jeffrey's total buy and sell value in the current window?
Inside the rolling retention window, DeLong Mark Jeffrey bought $0 and sold $147K based on SEC Form 4 filings.
What was DeLong Mark Jeffrey's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 3,371 APLS shares on 2026-01-22, worth $73K, per SEC Form 4 filings.